Gedeon Richter and Actavis Announce FDA Receipt of NDA Resubmission for Cariprazine

Gedeon Richter Plc. and Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis’ New Drug Application (NDA) resubmission.